This review discusses the evidence in support of the use of Angiomax® (bivalirudin), a thrombin-
specific anticoagulant that is indicated for use as an anticoagulant in the treatment of patients with
moderate to high risk acute coronary syndromes (ACS) (unstable angina, non-ST-elevation myocardial
infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]) who are undergoing early invasive
management, and in patients undergoing percutaneous coronary intervention (PCI).
Download PDF